Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector.
about
Pros and Cons of Antigen-Presenting Cell Targeted Tumor VaccinesPeptide-based technologies to alter adenoviral vector tropism: ways and means for systemic treatment of cancerTrafficking of phagocytic peritoneal cells in hypoinsulinemic-hyperglycemic mice with systemic candidiasisAnti-CD27 Antibody Potentiates Antitumor Effect of Dendritic Cell-Based Vaccine in Prostate Cancer-Bearing Mice.Incorporation of porcine adenovirus 4 fiber protein enhances infectivity of adenovirus vector on dendritic cells: implications for immune-mediated cancer therapy.Functional Specialty of CD40 and Dendritic Cell Surface Lectins for Exogenous Antigen Presentation to CD8(+) and CD4(+) T CellsDendritic cells serve as a "Trojan horse" for oncolytic adenovirus delivery in the treatment of mouse prostate cancerImmunological suppression of head and neck carcinoma by dendritic cell tumor fusion vaccine.Dendritic cell targeting vaccine for HPV-associated cancerReprogramming the conduction system: Onward toward a biological pacemaker.The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological diseaseAntitumor effects of oncolytic adenovirus armed with PSA-IZ-CD40L fusion gene against prostate cancer.Epstein Barr virus Latent Membrane Protein-1 enhances dendritic cell therapy lymph node migration, activation, and IL-12 secretion.Development of an adenovirus vector vaccine platform for targeting dendritic cells.
P2860
Q27013679-E5826F14-FC3D-45C7-8A10-A472E26F446CQ33584756-12F9F205-6C31-4EF8-B0E9-7DB810002B1FQ34632356-C1163075-9288-4FEE-901B-A21736AF37B6Q34993204-AC0B80FE-32D1-4DB0-8BF0-31F32AA971C3Q35620238-F16B09CC-87C7-424D-B52F-E0FB0CFEB2C3Q36754182-2E00D990-ED94-4B5C-B1EA-E086BE4F3F9CQ37151620-7811DB38-1066-40E8-9775-8B0183AA50F6Q37325047-AD21D331-AAE8-4BA6-A827-E87B0810636CQ37607686-09955A64-C3F1-4CDE-A007-CA4F97AA1DBAQ38456300-1E143900-41D0-4AB1-B91D-F31FCE3C0BD2Q38831232-20E17E7C-FBFC-4F20-9156-1CC4DE4242D1Q38992973-6E094CB3-6154-45DB-BDA0-3231AF61A0E1Q40041237-9A7414D1-6584-4963-A5C6-718AA2705203Q47248134-EA8C4F16-2643-456D-956E-F682559C3947
P2860
Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector.
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
Dendritic cell based PSMA immu ...... 40-targeted adenovirus vector.
@ast
Dendritic cell based PSMA immu ...... 40-targeted adenovirus vector.
@en
Dendritic cell based PSMA immu ...... 40-targeted adenovirus vector.
@nl
type
label
Dendritic cell based PSMA immu ...... 40-targeted adenovirus vector.
@ast
Dendritic cell based PSMA immu ...... 40-targeted adenovirus vector.
@en
Dendritic cell based PSMA immu ...... 40-targeted adenovirus vector.
@nl
prefLabel
Dendritic cell based PSMA immu ...... 40-targeted adenovirus vector.
@ast
Dendritic cell based PSMA immu ...... 40-targeted adenovirus vector.
@en
Dendritic cell based PSMA immu ...... 40-targeted adenovirus vector.
@nl
P2093
P2860
P1433
P1476
Dendritic cell based PSMA immu ...... 40-targeted adenovirus vector.
@en
P2093
Alexander V Pereboev
Briana Jill Williams
Donna L Rogers
J Michael Mathis
Jennifer L Carroll
Lisa K Adams
Nikolay Korokhov
Shilpa Bhatia
Susan Boling
Xiao-Lin Li
P2860
P304
P356
10.1371/JOURNAL.PONE.0046981
P407
P577
2012-10-08T00:00:00Z